Heska Corp (NASDAQ:HSKA) saw a large increase in short interest in the month of June. As of June 30th, there was short interest totalling 690,000 shares, an increase of 14.6% from the May 30th total of 602,000 shares. Currently, 10.1% of the company’s shares are sold short. Based on an average daily volume of 87,400 shares, the days-to-cover ratio is presently 7.9 days.

In other Heska news, Director Scott Humphrey bought 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The shares were bought at an average price of $73.79 per share, for a total transaction of $73,790.00. Following the transaction, the director now directly owns 3,062 shares in the company, valued at $225,944.98. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 14.00% of the stock is owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the business. Texas Permanent School Fund boosted its stake in shares of Heska by 3.8% during the 1st quarter. Texas Permanent School Fund now owns 4,638 shares of the medical research company’s stock valued at $395,000 after purchasing an additional 168 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Heska by 1.0% during the 1st quarter. Rhumbline Advisers now owns 19,630 shares of the medical research company’s stock valued at $1,671,000 after purchasing an additional 191 shares in the last quarter. Manchester Capital Management LLC boosted its stake in shares of Heska by 128.6% during the 1st quarter. Manchester Capital Management LLC now owns 400 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 225 shares in the last quarter. Legal & General Group Plc boosted its stake in shares of Heska by 1.8% during the 4th quarter. Legal & General Group Plc now owns 14,631 shares of the medical research company’s stock valued at $1,278,000 after purchasing an additional 258 shares in the last quarter. Finally, US Bancorp DE boosted its stake in shares of Heska by 1.8% during the 1st quarter. US Bancorp DE now owns 21,164 shares of the medical research company’s stock valued at $1,801,000 after purchasing an additional 374 shares in the last quarter. Hedge funds and other institutional investors own 88.96% of the company’s stock.

Shares of HSKA stock traded down $2.04 during mid-day trading on Friday, reaching $80.77. The stock had a trading volume of 60,147 shares, compared to its average volume of 82,162. The company has a 50-day moving average price of $78.46. Heska has a 52-week low of $68.74 and a 52-week high of $114.50. The company has a market capitalization of $625.97 million, a price-to-earnings ratio of 56.88 and a beta of 0.96. The company has a quick ratio of 1.45, a current ratio of 2.66 and a debt-to-equity ratio of 0.04.

Heska (NASDAQ:HSKA) last released its quarterly earnings data on Tuesday, May 7th. The medical research company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.19. Heska had a net margin of 3.63% and a return on equity of 8.36%. The firm had revenue of $29.51 million for the quarter, compared to analysts’ expectations of $35.21 million. Equities analysts forecast that Heska will post 0.03 earnings per share for the current year.

HSKA has been the topic of a number of analyst reports. BidaskClub upgraded shares of DENTSPLY SIRONA from a “buy” rating to a “strong-buy” rating in a research report on Thursday, June 13th. Guggenheim reiterated a “buy” rating and issued a $95.00 target price (up previously from $90.00) on shares of VF in a research report on Thursday, May 23rd. ValuEngine cut shares of Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. Finally, Canaccord Genuity reiterated a “speculative buy” rating and issued a GBX 70 ($0.91) target price on shares of Bacanora Lithium in a research report on Monday, July 1st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company. Heska presently has a consensus rating of “Hold” and an average price target of $103.25.

About Heska

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.

Featured Story: What is the S&P 500 Index?

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.